EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis

Nicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, Yolanda Blanco, Harald Hegen iD, Klaus Berek, Francisco Pérez-Miralles, Konrad Rejdak, Luisa Villar, Enric Monreal, Roberto Alvarez-Lafuente, Franziska Bachhuber und 15 weitere

European Journal of Neurology · 2026

DOI: 10.1111/ene.70480 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Nicolás Fissolo und 26 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebro…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Chronic Progressive, Disease Progression, Receptors, Immunologic, Membrane Glycoproteins. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca" (AGAUR; Generalitat de Catalunya) through Consolidated Research Groups.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglia surface receptor that aids in tissue repair and debris clearance. The soluble form, sTREM2, found in both blood and cerebrospinal fluid, is considered a biomarker for microglial activation. Based on the central role of microglia in MS pathogenesis, we aimed to investigate whether serum sTREM2 levels could predict disability progression in patients with primary progressive MS.

Methods

Serum levels of sTREM2 were measured at baseline using a single‐molecule array assay in a multicenter cohort of 137 primary progressive multiple sclerosis (PPMS) patients. Univariable and multivariable linear models evaluated the association between sTREM2 levels and EDSS change at 2 years, 6 years, and last follow‐up.

Results

While an association was observed at 2 years only in non‐inflammatory PPMS patients, no consistent relationship was found between sTREM2 levels and disability progression over longer follow‐up.

Conclusions

These findings suggest that serum sTREM2 may have limited value as a biomarker of disability progression in PPMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Chronic ProgressiveDisease ProgressionReceptors, ImmunologicMembrane GlycoproteinsHumansFemaleMaleBiomarkersMiddle AgedAdultDisability Evaluation

Stichwörter der Autor:innen

biomarkersdisability progressionprimary progressive multiple sclerosissTREM2

Substanzen

Receptors, ImmunologicTREM2 protein, humanMembrane GlycoproteinsBiomarkers

Autor:innen und Institutionen

  • Servei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) - ISCIII, Madrid, Spain.
  • Department of Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland.
  • Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.
  • Center of Neuroimmunology, Service of Neurology, Hospital Clinic, Institut D'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Harald Hegen, Roberto Furlan

Förderung

  • Agència de Gestió d'Ajuts Universitaris i de Recerca" (AGAUR; Generalitat de Catalunya) through Consolidated Research Groups

Zitieren

APA

Fissolo, N., Benkert, P., Vilaseca-Jolonch, A., Blanco, Y., Hegen, H., Berek, K., Pérez-Miralles, F., Rejdak, K., Villar, L., Monreal, E., Alvarez-Lafuente, R., Bachhuber, F., Tumani, H., Martínez-Yelamos, S., Sánchez-López, A., García-Merino, A., Gutiérrez, L., Castillo-Triviño, T., Lycke, J., …, & Comabella, M. (2026). Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70480

Vancouver

Fissolo N, Benkert P, Vilaseca-Jolonch A, Blanco Y, Hegen H, Berek K, et al. Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis. European Journal of Neurology. 2026. doi:10.1111/ene.70480

BibTeX
@article{Fissolo2026,
  author = {Fissolo, Nicolás and Benkert, Pascal and Vilaseca-Jolonch, Andreu and Blanco, Yolanda and Hegen, Harald and Berek, Klaus and Pérez-Miralles, Francisco and Rejdak, Konrad and Villar, Luisa and Monreal, Enric and Alvarez-Lafuente, Roberto and Bachhuber, Franziska and Tumani, Hayrettin and Martínez-Yelamos, Sergio and Sánchez-López, Antonio and García-Merino, Antonio and Gutiérrez, Lucía and Castillo-Triviño, Tamara and Lycke, Jan and Rosenstein, Igal and Téllez, Nieves and Furlan, Roberto and Lünemann, Jan D and Khalil, Michael and Kuhle, Jens and Montalban, Xavier and Comabella, Manuel},
  title = {Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70480}
}
Kostenlos starten →